An interventional study of Bupivacaine Hcl 0.25% ESP block and Bupivacaine Hcl 0.25% infiltration in Colorectal Cancer and Postoperative Pain, sponsored by Ataturk University. Status unknown at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-04.
Sponsored by Ataturk University · Not applicable, Interventional, and Treatment
Colorectal cancer is a common and lethal disease. It still remains the third most common cause of cancer death in women and the second leading cause of death in men. Pain control is an important direction of postoperative management in malignancy surgery. Inadequate pain control increases cardiac and respiratory complications in these critical patients. Erector spinae plane (ESP) block is a recently described regional anesthesia technique that blocks the dorsal and ventral rami of the spinal nerves and the sympathetic nerve fibers. While the ESP block has been shown to provide effective postoperative analgesia after thoracic, and abdominal surgeries.
Our aim in this study was to investigate bilateral thoracic ESP block for providing successful postoperative pain management following colorectal surgery.
5,734 studies on the registry are indexed under Colorectal Neoplasms; 1,481 are open to participants now.
This study's planned enrollment of 48 is below the median of 77 across 4,222 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Ataturk University is the lead sponsor of 454 studies on the registry; 123 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
Drug: Bupivacaine Hcl 0.25% ESP block
Wound infiltration with 20 ml %0.25 bupivacaine
Drug: Bupivacaine Hcl 0.25% infiltration
Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
Wound infiltration with 20 ml %0.25 bupivacaine
Opioid Consumption
Opioid consumption postroperative period
Time frame: Postoperative first 24 hours
Visual Analog Pain Score
Pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain)
Time frame: Postoperative first 24 hours
Start is estimated for Jun 2020; primary completion for Jul 2020, 1 month later.
Of 801 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 1 month is below that.
Counting every sponsor, half of 845 studies reached it within 32 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine